Abata Therapeutics

Senior Director, Quality Assurance

Burlington, Massachusetts, United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Central Nervous System DisordersIndustries

Requirements

Candidates should possess an advanced degree and at least 15 years of progressive leadership experience in Quality within a biotechnology company. Deep expertise in ICH, FDA, and EMA guidelines is required, along with a strong track record of managing audits.

Responsibilities

The Senior Director, Quality Assurance will partner with the VP QA to develop and implement comprehensive Quality Assurance strategies for pharmaceutical product manufacturing, testing, and release in accordance with GxP regulations. They will design and implement policies and practices to ensure GxP compliance, lead a quality culture, and ensure organizational processes conform with standard operating procedures. This role involves contributing to inspection and audit strategies, performing lot release activities, supporting the Quality Management System (QMS) for GMP, GLP, and GCP compliance, and collaborating with cross-functional teams to integrate quality processes. Responsibilities also include conducting risk assessments, supporting regulatory inspections and responses, establishing KPIs, driving training programs, and implementing continuous improvement initiatives. Additionally, the role supports IND and NDA CMC module authoring, vendor oversight, batch record review, deviation investigations, and compliance with applicable regulations such as FDA and ICH.

Skills

Quality Assurance
GxP Compliance
Quality Management System (QMS)
GMP
GLP
GCP
Risk Assessment
Regulatory Inspections
Audits
Lot Release
Pharmaceutical Manufacturing
Pharmaceutical Testing
Pharmaceutical Release

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI